Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

CHNA vs. SHSSX: which is better?

Bottom line

CHNA vs SHSSX: the short answer

CHNA (Loncar China BioPharma ETF) and SHSSX (Blackrock Health Sciences Opportunities Portfolio) are both etfs.

Updated Nov 19, 2026

CHNA vs SHSSX side by side

CHNASHSSX
TypeETFMutual fund
Fund familyGrayscaleBlackRock
CategoryHealth Care SectorHealth Care Sector
Expense ratio—0.86%
Annual cost per $10k—$86
10-yr cost on $10k (prospectus)—$1,061
Max front loadNone0%
12b-1 fee—0%
1-yr return—+16.3%
5-yr return (annualized)—+5.9%
10-yr return (annualized)—+9.8%
Best quarter——
Worst quarter——
Net assets (fund)—$5.9B
Number of holdings—155
Portfolio turnover—49%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

CHNA and SHSSX share none of their top holdings.

CHNA top 10

    SHSSX top 10

    1. Eli Lilly & Company — 12.29%
    2. Johnson & Johnson — 8.77%
    3. Unitedhealth Group Inc — 6.10%
    4. Merck & Company Inc — 4.94%
    5. Gilead Sciences Inc — 4.19%
    6. Abbvie Inc — 3.94%
    7. Amgen Inc — 3.37%
    8. Thermo Fisher Scientific Inc — 3.02%
    9. Vertex Pharmaceuticals Inc — 2.74%
    10. Pfizer Inc — 2.61%

    FAQ

    What is the difference between CHNA and SHSSX?
    CHNA (Loncar China BioPharma ETF) and SHSSX (Blackrock Health Sciences Opportunities Portfolio) are both etfs.
    Should I own both CHNA and SHSSX?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.